DualWMDR: Detecting epistatic interaction with dual screening and multifactor dimensionality reduction.

Journal: Human mutation
PMID:

Abstract

Detecting epistatic interaction is a typical way of identifying the genetic susceptibility of complex diseases. Multifactor dimensionality reduction (MDR) is a decent solution for epistasis detection. Existing MDR-based methods still suffer from high computational costs or poor performance. In this paper, we propose a new solution that integrates a dual screening strategy with MDR, termed as DualWMDR. Particularly, the first screening employs an adaptive clustering algorithm with part mutual information (PMI) to group single nucleotide polymorphisms (SNPs) and exclude noisy SNPs; the second screening takes into account both the single-locus effect and interaction effect to select dominant SNPs, which effectively alleviates the negative impact of main effects and provides a much smaller but accurate candidate set for MDR. After that, MDR uses the weighted classification evaluation to improve its performance in epistasis identification on the candidate set. The results on diverse simulation datasets show that DualWMDR outperforms existing competitive methods, and the results on three real genome-wide datasets: the age-related macular degeneration (AMD) dataset, breast cancer (BC), and celiac disease (CD) datasets from the Wellcome Trust Case Control Consortium, again corroborate the effectiveness of DualWMDR.

Authors

  • Xia Cao
    College of Computer and Information Science, Southwest University, Chongqing, China.
  • Guoxian Yu
    College of Computer and Information Science, Southwest University, Chongqing 400715, China Key Laboratory of Symbolic Computation and Knowledge Engineering of Ministry of Education, Jilin University, Changchun 130012, China.
  • Wei Ren
    Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Department of Medical Oncology, Breast Tumor Centre, Phase I Clinical Trial Centre, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • Maozu Guo
    School of Computer Science and Technology, Harbin Institute of Technology, Harbin, Heilongjiang, China.
  • Jun Wang
    Department of Speech, Language, and Hearing Sciences and the Department of Neurology, The University of Texas at Austin, Austin, TX 78712, USA.